The DOI matches its Crossref record.
Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study.
Abstract
PURPOSE: The aim of this study was to evaluate the efficacy and toxicity of gemcitabine at higher doses than had been used previously in patients with non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS: Eighty-four patients (65 men, 19 women; age range, 35 to 75 years; mean age, 59 years) with locally advanced or metastatic pathologically documented NSCLC were enrolled. Patients had bidimensionally measurable disease, as defined by computed tomographic (CT) scan or chest x-ray. A total of 28.6% had previously been surgically treated, while 9.5% had received radiotherapy. Fifty-three patients commenced at a dose of 1,000 mg/m2, and 31 at a dose of 1,250 mg/m2. Patients were to receive two dose escalations of 25%, provided that overall toxicity was no worse than World Health Organization (WHO) grade 1 or WHO grade 0 for platelets. Responding patients were reviewed and validated by a blinded oncology review board (ORB) of experts not involved with the study. Of the original 84 patients enrolled, 76 were assessable. RESULTS: The overall response rate was 20% (95% confidence interval [CI], 11.6% to 30.8%). There were two complete responses (3%) and 13 partial responses (17%). Hematologic toxicity was negligible. WHO grade 3 WBC toxicity occurred in 0.9% of doses and WHO grade 4 in 0.1%. WHO grade 3 and 4 thrombocytopenia occurred in 0.1% and 0.1% of all doses, respectively. Nonhematologic toxicity was minor and easily controlled. Common side effects included peripheral edema, asthenia, and transient malaise. CONCLUSION: The single-agent efficacy of gemcitabine is equivalent to other agents commonly used to treat NSCLC. Gemcitabine has an unusually mild side effect profile for such an active agent. The nausea and vomiting experienced with gemcitabine are mild and generally well controlled with standard antiemetics; 5-HT3 receptor antagonists are typically not required. The use of gemcitabine does not cause significant alopecia, and hematologic toxicity is modest and unlikely to require hospitalization. Gemcitabine may have a role as monotherapy in patients with inoperable NSCLC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Shelton, J., Lu, X., Hollenbaugh, J. A., Cho, J. H., Amblard, F., & Schinazi, R. F. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00209 · Cited by 409
Role of gemcitabine in cancer therapy
Toschi, L., Finocchiaro, G., Bartolini, S., Gioia, V, & Cappuzzo, F. (2005) · Future Oncology · doi:10.1517/14796694.1.1.7 · Cited by 373
Crinò, L., Scagliotti, G. V., Ricci, S., De Marinis, F., Rinaldi, M., Gridelli, C., Ceribelli, A., Bianco, R., Marangolo, M., Di Costanzo, F., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.11.3522 · Cited by 362
Determinants of resistance to 2′,2′-difluorodeoxycytidine (gemcitabine)
Bergman, A. M., Pinedo, H. M., & Peters, G. J. (2002) · Drug Resistance Updates · doi:10.1016/s1368-7646(02)00002-x · Cited by 360
Advanced breast cancer: a phase II trial with gemcitabine.
Carmichael, J., Possinger, K., Phillip, P., Beykirch, M., Kerr, H., Walling, J., & Harris, A. L. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.11.2731 · Cited by 338
Metadata
- Authors
- Abratt, R. P., Bezwoda, W. R., Falkson, G., Goedhals, L., Hacking, D., & Rugg, T. A.
- Venue
- Journal of Clinical Oncology
- Published
- 1994-08
- Volume
- 12
- Issue
- 8
- Pages
- 1535-1540
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1857358013
- Cited by
- 359
- References
- 0
- FWCI
- 22.26
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study. https://app.cochat.ai/papers/10.1200/jco.1994.12.8.1535
- The paper
- Abratt, R. P., Bezwoda, W. R., Falkson, G., Goedhals, L., Hacking, D., & Rugg, T. A. (1994). Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study. Journal of Clinical Oncology. https://doi.org/10.1200/jco.1994.12.8.1535
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.